-
1
-
-
0025861545
-
Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: A meta-analysis
-
The Ovarian Cancer Meta-Analysis Project. Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. J Clin Oncol 1991; 9: 1668-74.
-
(1991)
J Clin Oncol
, vol.9
, pp. 1668-1674
-
-
-
2
-
-
0026679287
-
Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma
-
Fanning J, Bennet TZ, Hilgers RD. Meta-analysis of cisplatin, doxorubicin, and cyclophosphamide versus cisplatin and cyclophosphamide chemotherapy of ovarian carcinoma. Obstet Gynecol 1992; 80; 954-60.
-
(1992)
Obstet Gynecol
, vol.80
, pp. 954-960
-
-
Fanning, J.1
Bennet, T.Z.2
Hilgers, R.D.3
-
3
-
-
0028948614
-
Impact of doxorubicin on survival in advanced ovarian cancer
-
A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995; 13: 726-32.
-
(1995)
J Clin Oncol
, vol.13
, pp. 726-732
-
-
A'Hern, R.P.1
Gore, M.E.2
-
4
-
-
0030843953
-
Meta-analyses of chemotherapy regimens for ovarian carcinoma : A reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide
-
West RJ, Zweig SF. Meta-analyses of chemotherapy regimens for ovarian carcinoma : a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide. Eur J Gynaec Oncol 1997; 18: 343-8.
-
(1997)
Eur J Gynaec Oncol
, vol.18
, pp. 343-348
-
-
West, R.J.1
Zweig, S.F.2
-
5
-
-
0026055728
-
Chemotherapy in advanced ovarian cancer : An overview of randomized clinical trials
-
Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer : An overview of randomized clinical trials. Br Med J 1991; 303: 884-93.
-
(1991)
Br Med J
, vol.303
, pp. 884-893
-
-
-
6
-
-
0027724022
-
What have we learnt from metaanalyses in ovarian cancer ?
-
Kaye SB, Van Houwelingen HC. What have we learnt from metaanalyses in ovarian cancer ? Ann Oncol 1993; 4 (Suppl 4): S79-S82.
-
(1993)
Ann Oncol
, vol.4
, Issue.4 SUPPL.
-
-
Kaye, S.B.1
Van Houwelingen, H.C.2
-
7
-
-
0000433785
-
A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/Taxol (PT) in advanced ovarian cancer (AOC)
-
Abstr 808
-
McGuire WP, Hoskins WJ, Brady MF et al. for the Gynaecologic Oncology Group (GOG). A phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/Taxol (PT) in advanced ovarian cancer (AOC). Proc ASCO 1993; 12: 255 (Abstr 808).
-
(1993)
Proc ASCO
, vol.12
, pp. 255
-
-
McGuire, W.P.1
Hoskins, W.J.2
Brady, M.F.3
-
8
-
-
0000264166
-
Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer : Mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial
-
Abstr 1394
-
Stuart G, Bertelsen K, Mangioni C et al. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer : mature results of the EORTC-GCCG, NOCOVA, NCIC CTG and Scottish Intergroup Trial. Proc ASCO 1998; volume 17: 361a (Abstr 1394).
-
(1998)
Proc ASCO
, vol.17
-
-
Stuart, G.1
Bertelsen, K.2
Mangioni, C.3
-
9
-
-
0030054309
-
Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
-
McGuire WP, Hoskins WJ, Brady ME et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
-
(1996)
N Engl J Med
, vol.334
, pp. 1-6
-
-
McGuire, W.P.1
Hoskins, W.J.2
Brady, M.E.3
|